Literature DB >> 34798121

AgRP/NPY and POMC neurons in the arcuate nucleus and their potential role in treatment of obesity.

Muhammad Sufyan Vohra1, Khaled Benchoula1, Christopher J Serpell2, Wong Eng Hwa3.   

Abstract

Obesity is a major health crisis affecting over a third of the global population. This multifactorial disease is regulated via interoceptive neural circuits in the brain, whose alteration results in excessive body weight. Certain central neuronal populations in the brain are recognised as crucial nodes in energy homeostasis; in particular, the hypothalamic arcuate nucleus (ARC) region contains two peptide microcircuits that control energy balance with antagonistic functions: agouti-related peptide/neuropeptide-Y (AgRP/NPY) signals hunger and stimulates food intake; and pro-opiomelanocortin (POMC) signals satiety and reduces food intake. These neuronal peptides levels react to energy status and integrate signals from peripheral ghrelin, leptin, and insulin to regulate feeding and energy expenditure. To manage obesity comprehensively, it is crucial to understand cellular and molecular mechanisms of information processing in ARC neurons, since these regulate energy homeostasis. Importantly, a specific strategy focusing on ARC circuits needs to be devised to assist in treating obese patients and maintaining weight loss with minimal or no side effects. The aim of this review is to elucidate the recent developments in the study of AgRP-, NPY- and POMC-producing neurons, specific to their role in controlling metabolism. The impact of ghrelin, leptin, and insulin signalling via action of these neurons is also surveyed, since they also impact energy balance through this route. Lastly, we present key proteins, targeted genes, compounds, drugs, and therapies that actively work via these neurons and could potentially be used as therapeutic targets for treating obesity conditions.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AgRP/NPY; Arcuate nucleus (ARC); Insulin signalling; Leptin signalling; Obesity; POMC

Mesh:

Substances:

Year:  2021        PMID: 34798121     DOI: 10.1016/j.ejphar.2021.174611

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.

Authors:  Yilamujiang Ainiwan; Yiguang Chen; Chaofu Mao; Junxiang Peng; Siyuan Chen; Songtao Wei; Songtao Qi; Jun Pan
Journal:  J Neuroinflammation       Date:  2022-05-07       Impact factor: 9.587

Review 2.  Physiologic and pharmacologic considerations in morbid obesity and bariatric anesthesia.

Authors:  Kimberley C Brondeel; Alexis C Lakatta; Grant B Torres; Joshua J Hurley; Illan L Kunik; Kaley F Haney; Elyse M Cornett; Alan D Kaye
Journal:  Saudi J Anaesth       Date:  2022-06-20

3.  Epigenetic modifier Kdm6a/Utx controls the specification of hypothalamic neuronal subtypes in a sex-dependent manner.

Authors:  Lucas E Cabrera Zapata; María Julia Cambiasso; Maria Angeles Arevalo
Journal:  Front Cell Dev Biol       Date:  2022-10-04

Review 4.  Chrono-communication and cardiometabolic health: The intrinsic relationship and therapeutic nutritional promises.

Authors:  Pamela Senesi; Anna Ferrulli; Livio Luzi; Ileana Terruzzi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

Review 5.  The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review.

Authors:  Ruqin Zhou; Meng He; Jun Fan; Ruoxi Li; Yufeng Zuo; Benben Li; Guanbin Gao; Taolei Sun
Journal:  Front Neurosci       Date:  2022-09-16       Impact factor: 5.152

Review 6.  Genetics of Obesity in Humans: A Clinical Review.

Authors:  Ranim Mahmoud; Virginia Kimonis; Merlin G Butler
Journal:  Int J Mol Sci       Date:  2022-09-20       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.